I've read your posts in the past, and the general scorn you seem to extract from just about every other sane person on the planet, and up to now I've given you the benefit of the doubt. But the absolute rubbish you've proposed as representative of the FDA's likely position on the important issue of photosensitivity with PDT agents is unbelievable. I think you should go and sit in the sun for a while and get in touch with reality!
The FDA does not apply simple arithmetic logic in the manner you describe. They will select the safety period based on data, not simple extrapolation. I agree that it is likely that this period may be longer; how much longer can be speculated but not stated.
It was hilarious of you to state "That should be relatively clear to anyone with an open and objective mind". I suspect that nearly everyone who reads this board got a chuckle out of that, perhaps even you. You have been, are and always will be a QLTI homer to the exclusion of all fact and reality.
Regarding your conclusion that Visudyne is the safest and most convenient drug, one might argue that if the MRVT drug requires fewer retreatments, it may be more convenient than having to truck into the ophthalmologist's office every 13 weeks, eh?
Finally, keep on looking stupid by claiming that MRVT's drug is 2-3 years away. A child could do the math; MRVT's 12 month follow up ends in 12/00 and the NDA should be filed next year, 2001. If you think it will take 1-2 years for the FDA to review, fine by me. But you truly are becoming more of a simpleton as time goes on.
It is my opinion that if photopoint turns out to be even slightly better, people will seek it out more readily. I think people will do whatever it takes to get the most or preserve the most of their vision. Who really cares about 5-17 days. People, especially older people tend to want the latest and greatest treatments anyway(especially if the government is paying for it). If Photopoint turns out to be dramatically better, the sun-sensitiviy issue becomes a non-issue. QLTI stands on shakey ground. If Photopoint prelim data looks good, people will rapidly lose confidence in Visudyne. If Photopoint results don't shine than QLTI will be huge. Just my opinion. Be gentle.